DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infections

Intervention: Indinavir sulfate (Drug); Lamivudine (Drug); Zidovudine (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Dupont Merck

Summary

The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations. The three combinations are: (1) efavirenz (DMP 266) plus indinavir; (2) DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC); and (3) indinavir plus ZDV plus 3TC. This study also examines the resistance HIV may have to these drugs and if these drugs are effective over a long period of time.

Clinical Details

Official title: A Phase III, Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Different Combination Regimens (DMP 266 + Indinavir, DMP 266 + Zidovudine + Lamivudine, Indinavir + Zidovudine + Lamivudine) in HIV-Infected Patients

Study design: Treatment, Safety Study

Eligibility

Minimum age: 13 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Exclusion Criteria

Concurrent Medication:

Excluded:

- Terfenadine, astemizole, cisapride, triazolam, or midazolam (competition for the

enzyme cytochrome P-450 3A4 [CYP3A4] by indinavir could result in inhibition of metabolic breakdown of these drugs and create the potential for serious and/or life threatening events [i. e., cardiac arrhythmia, prolonged sedation]).

- Rifampin or rifabutin (prohibited because of potential drug interaction with

indinavir).

- Ketoconazole, itraconazole, and clarithromycin.

- Concomitant systemic therapy for acute opportunistic infection or malignancy.

Excluded:

Life expectancy less than 12 months.

Prior Medication:

Excluded:

- Prior treatment with efavirenz, 3TC, an NNRTI, or an HIV protease inhibitor.

- Prior antiretroviral agent within 14 days of initiating study treatment.

- Prior treatment (within 30 days of initiating study treatment) with any other

experimental drug for any indication.

Patients must:

- Have a diagnosis of HIV infection.

- Have CD4 counts greater than or equal to 50 cell/mm3.

- Have a life expectancy greater than or equal to 12 months.

- Be post-pubescent.

Locations and Contacts

Javier O Morales Ramirez, San Juan 00909, Puerto Rico

Phoenix Body Positive, Phoenix, Arizona 85016, United States

Arizona Clinical Research Ctr Inc, Tucson, Arizona 85712, United States

Paul Cimoch, Irvine, California 92618, United States

Richard Stryker, Beverly Hills, California 90210, United States

AIDS Healthcare Foundation, Los Angeles, California 90027, United States

Oasis Clinic / Martin Luther Jr Gen Hosp / King-Drew Med Ctr, Los Angeles, California 90059, United States

Kraus Med Group, Los Angeles, California 90036, United States

Blick Med Associates, Stamford, Connecticut 06901, United States

Novum Inc, Washington, District of Columbia 20037, United States

Treasure Coast Infectious Disease Consultants, Vero Beach, Florida 32960, United States

Infectious Disease Research Institute, Tampa, Florida 33614, United States

Bach and Godofsky, Bradenton, Florida 34205, United States

Boulevard Comprehensive Care Ctr, Jacksonville, Florida 32209, United States

Daniel Seekins, Tampa, Florida 33614, United States

Ctr for Quality Care, Tampa, Florida 33609, United States

Larry Marc Bush / c/o Sally Yantis, Lake Worth, Florida 33463, United States

Univ of Miami School of Medicine, Miami, Florida 33136, United States

Community Research Initiative of South Florida, Coral Gables, Florida 33146, United States

Med College of Georgia, Augusta, Georgia 30912, United States

Georgia Research Associates, Atlanta, Georgia 30342, United States

Infectious Diseases, Indianapolis, Indiana 46202, United States

Univ of Kentucky Med Ctr, Lexington, Kentucky 40536, United States

Kansas City AIDS Research Consortium, Kansas City, Missouri 64111, United States

Univ of Nebraska Med Ctr / HIV Clinic, Omaha, Nebraska 681985400, United States

Univ Med Ctr / HIV Wellness Ctr, Las Vegas, Nevada 89102, United States

Community Research Initiative on AIDS, New York, New York 10001, United States

Clinical Directors Network / HIV/AIDS Program Manager, New York, New York 10011, United States

Wake Forest Univ School of Medicine, Winston Salem, North Carolina 27157, United States

Remington-Davis Inc, Columbus, Ohio 43215, United States

Philadelphia FIGHT, Philadelphia, Pennsylvania 19107, United States

The Miriam Hosp, Providence, Rhode Island 02906, United States

Division of Infectious Disease / Dept of Internal Medicine, Dallas, Texas 752359113, United States

UT-Health Science Ctr, Houston, Texas 77030, United States

Diagnostic Clinic of San Antonio, San Antonio, Texas 78229, United States

Montrose Clinic, Houston, Texas 77006, United States

Research Services 2000 Inc, Fort Worth, Texas 76103, United States

Research Services 2000 Inc, Dallas, Texas 75208, United States

Oyster Point Med Specialists, Newport News, Virginia 23606, United States

Novum Inc / Pharmaceutical Research Services, Seattle, Washington 98122, United States

Infectious Diseases Associates, Milwaukee, Wisconsin 53215, United States

Additional Information


Last updated: June 23, 2005

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009